← Back to headlines
MannKind Corporation Stock Up 20% Post-FDA Approval
MannKind Corporation (MNKD) has seen its stock price increase by 20% following the FDA approval of its product, Afrezza. This surge reflects positive market reaction to the regulatory milestone.
9 Jul, 17:29 — 9 Jul, 17:29
Sources
Showing 1 of 1 sources
